Skip to main content
italianoIT
European Commission logo print header

Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies

Descrizione del progetto

DEENESFRITPL

Tecnologia di imaging per la valutazione dello stato immunitario del paziente

L’immunoterapia può trattare in modo efficace determinate patologie gravi quali il cancro e le malattie infiammatorie, ma è fondamentale un approccio personalizzato. I marcatori di sangue e tessuti associati all’imaging non invasivo potrebbero aiutare nella valutazione dello stato immunitario in vivo, ma quest’opzione è stata poco esplorata. A tal fine, il progetto finanziato dall’UE svilupperà nuovi immunotraccianti per l’imaging di specifiche serie di cellule immunitarie, per poi convalidarli nei modelli di malattia pertinenti. L’obiettivo è trasferirli in produzione e poi condurre sperimentazioni cliniche intelligenti. Questo consorzio multidisciplinare internazionale agirà sull’ottimizzazione delle tecniche di imaging molecolari per la valutazione dello stato immunitario del paziente, tramite immunotraccianti e con lo sviluppo di farmaci immunoterapeutici personalizzati.

Obiettivo

Immunotherapies have emerged as effective treatments for immune system-related diseases, such as cancer and inflammatory diseases. Although immunotherapeutics are effective not all patients benefit and side effects vary greatly. Thus, there is an unmet need for a personalized approach. Blood and tissue biomarkers have played only a modest role up until now in assessing immune status in vivo and we believe that non-invasive whole body imaging will make a significant contribution in the future. Although the field of imaging (PET, MRI, Optical Imaging) is flourishing, its application to patient immune status measurement and monitoring has barely been explored. Within Immune-Image we aim to develop new immunotracers for imaging specific immune cell subsets, develop quantitative imaging workflows, validate the immunotracers pre-clinically in relevant disease models, produce the tracers in a Good Manufacturing Practice (GMP)-compliant way, and conduct smart clinical trials, including with novel tracers.
To this end, insights will be gained into the optimal use of drugs and a more efficient development of immunotherapeutics. Moreover, the success rate of immunotherapy development will be enhanced since our molecular imaging platform will provide novel insights into patient immune status, which will support drug development and treatment decisions.
To achieve our goals, we have assembled an experienced international multi-disciplinary consortium composed of chemists, biologists, immunologists, physicists, pharmacists, information technologists, and medical specialists with diverse and essential backgrounds who will join forces to design, synthesise, evaluate and validate immunotracers and create sustainable molecular imaging techniques that can be broadly applied in the assessment of the immune status and immune modulation of patients. There will be input from patients and regulators in order to assure optimal design and execution of immunotracer clinical trials.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-JTI-IMI2-2018-14-two-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

STICHTING VUMC
Contribution nette de l'UE
€ 3 903 722,00
Indirizzo
De boelelaan 1117
1081 HV Amsterdam
Paesi Bassi

Mostra sulla mappa
Regione
West-Nederland Noord-Holland Groot-Amsterdam
Tipo di attività
Research Organisations
Collegamenti
Altri finanziamenti
€ 1 397 000,50

Partecipanti (25)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 5 Dicembre 2023

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/831514/it

European Union, 2023